BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+13.22%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$25B
AUM Growth
+$25B
(+10%)
Cap. Flow
+$849M
Cap. Flow
% of AUM
3.39%
Top 10 Holdings %
Top 10 Hldgs %
85.68%
Holding
126
New
11
Increased
17
Reduced
63
Closed
6
Top Buys
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$437M |
| 2 |
Prelude Therapeutics
PRLD
|
$305M |
| 3 |
Kymera Therapeutics
KYMR
|
$63.3M |
| 4 |
Nurix Therapeutics
NRIX
|
$62.5M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$48.2M |
Top Sells
| 1 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
$94.5M |
| 2 |
Insmed
INSM
|
$24.2M |
| 3 |
Neurocrine Biosciences
NBIX
|
$22.1M |
| 4 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$21.6M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$21.1M |
Sector Composition
| 1 | Healthcare | 97.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
| $9.25B | 36.96% | 47,269,424 | – | – |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $3.81B | 15.22% | 13,301,597 +1,524,312 | +13% | +$437M |
|
3
Incyte
INCY
$16.5B
| $2.87B | 11.47% | 31,999,398 +317 | +0% | +$28.4K |
|
4
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.73B | 6.91% | 41,904,586 | – | – |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $1B | 4.01% | 8,760,794 | – | – |
|
6
Kodiak Sciences
KOD
$478M
| $731M | 2.92% | 12,352,175 +777,637 | +7% | +$46M |
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $577M | 2.31% | 7,589,294 | – | – |
|
8
Ascendis Pharma
ASND
$11.8B
| $546M | 2.18% | 3,540,270 +150,000 | +4% | +$23.1M |
|
|
NVTA
9
DELISTED
Invitae Corporation
NVTA
| $514M | 2.05% | 11,850,962 | – | – |
|
|
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $410M | 1.64% | 3,009,344 -154,890 | -5% | -$21.1M |
|
|
11
Prelude Therapeutics
PRLD
$68.5M
| $305M | 1.22% | +10,118,636 | New | +$305M |
|
12
argenx
ARGX
$43.6B
| $268M | 1.07% | 1,019,557 | – | – |
|
|
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $234M | 0.94% | 1,409,784 | – | – |
|
|
IGMS
14
DELISTED
IGM Biosciences
IGMS
| $232M | 0.93% | 3,144,446 +223 | +0% | +$16.5K |
|
15
Exact Sciences
EXAS
$8.98B
| $188M | 0.75% | 1,846,139 | – | – |
|
16
Madrigal Pharmaceuticals
MDGL
$9.76B
| $178M | 0.71% | 1,499,213 +1 | +0% | +$119 |
|
|
AMRN
17
Amarin Corp
AMRN
$311M
| $135M | 0.54% | 32,018,867 -2,477,818 | -7% | -$10.4M |
|
18
Heron Therapeutics
HRTX
$207M
| $88.8M | 0.36% | 5,994,704 -23,400 | -0.4% | -$347K |
|
|
FMTX
19
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $88.3M | 0.35% | 1,771,509 -228,491 | -11% | -$11.4M |
|
20
Cerus
CERS
$251M
| $85.8M | 0.34% | 13,713,195 | – | – |
|
21
Zymeworks
ZYME
$1.12B
| $79.6M | 0.32% | 1,708,472 | – | – |
|
|
22
Insmed
INSM
$28.8B
| $73M | 0.29% | 2,272,712 -752,672 | -25% | -$24.2M |
|
23
Axsome Therapeutics
AXSM
$6.05B
| $68.4M | 0.27% | 959,757 -50,000 | -5% | -$3.56M |
|
|
24
Neurocrine Biosciences
NBIX
$13.8B
| $65.1M | 0.26% | 676,975 -230,011 | -25% | -$22.1M |
|
|
25
Kymera Therapeutics
KYMR
$2.95B
| $63.3M | 0.25% | +1,959,211 | New | +$63.3M |
|